DL-2-Hydroxyisocaproic Acid Attenuates Inflammatory Responses in a Murine Candida albicans Biofilm Model

M. T. Nieminen, a,b,d M. Hernandez, a L. Novak-Frazer, d H. Kuula, b G. Ramage, f P. Bowyer, d P. Warn, d T. Sorsa, b,c R. Rautemaad

Research Unit on Acetaldehyde and Cancer, University of Helsinki, Helsinki, Finland; Departments of Periodontology and Oral and Maxillofacial Diseases, Helsinki University Central Hospital, University of Helsinki, Helsinki, Finland; Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Huddinge, Sweden; The University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Science Centre, University Hospital of South Manchester, Wythenshawe Hospital, Manchester, United Kingdom; Department of Oral Pathology and Medicine and Laboratory of Periodontal Biology, Faculty of Dentistry, Universidad de Chile, Santiago, Chile; Infection and Immunity Research Group, Glasgow Dental School and Hospital, School of Medicine, College of Medicine, Veterinary and Life Sciences, Faculty of Medicine, University of Glasgow, Glasgow, United Kingdom.

Chronic biofilm infections are often accompanied by a chronic inflammatory response, leading to impaired healing and increased, irreversible damage to host tissues. Biofilm formation is a major virulence factor for Candida albicans and a challenge for treatment. Most current antifungals have proved ineffective in eradicating infections attributed to biofilms. The biofilm structure protects Candida species against antifungals and provides a way for them to evade host immune systems. This leads to a very distinct inflammatory response compared to that seen in planktonic infections. Previously, we showed the superior efficacy of DL-2-hydroxyisocaproic acid (HICA) against various bacteria and fungi. However, the immunomodulatory properties of HICA have not been studied. Our aim was to investigate the potential anti-inflammatory response to HICA in vivo. We hypothesized that HICA reduces the levels of immune mediators and attenuates the inflammatory response. In a murine model, a robust biofilm was formed for 5 days in a diffusion chamber implanted underneath mouse skin. The biofilm was treated for 12 h with HICA, while caspofungin and phosphate-buffered saline (PBS) were used as controls. The pathophysiology and immunomodulatory potential in the tissues surrounding the chamber were determined by immunohistochemistry. Histopathological examination showed an attenuated inflammatory response together with reduced expression of matrix metalloproteinase 9 (MMP-9) and myeloperoxidase (MPO) compared to those of chambers containing caspofungin and PBS. Interestingly, the expression of developmental endothelial locus 1 (Del-1), an antagonist of neutrophil extravasation, increased after treatment with HICA. Considering its anti-inflammatory and antimicrobial activity, HICA may have enormous therapeutic potential in the treatment of chronic biofilm infections and inflammation, such as those seen with chronic wounds.

Approximately 65% of human infections are biofilm related (1). A residing biofilm infection often causes aggravated inflammation in host tissues, thus leading to a chronic inflammatory status (2). Chronic inflammatory responses complicate healing and cause increased and irreversible damage to host tissues, which is characteristic of chronic wounds and periodontitis (3, 4).

Candida albicans is an opportunistic fungal pathogen that causes superficial and systemic infections in humans (5). Infection arises when the yeast is able to overcome the host immune response, and this interplay is regulated by pro- and anti-inflammatory mediators. The extracellular carbohydrate matrix of biofilms provides a very distinctive and protective niche in which yeast cells can grow within the host, and the cells often show an altered phenotype and antifungal resistance profile compared to those of planktonic counterparts (6, 7). The cells embedded within biofilms are able to evade host immune cells since the cell surface structures are masked (1). Very few studies have assessed the inflammatory response induced by C. albicans biofilm in vivo (8–10).

The management of Candida infections with commonly used antifungals is challenging due to poor efficacy, poor patient compliance, and numerous side effects and interactions (5). The most promising antifungal activity has been observed with the echinocandin class of antifungals, which are noncompetitive inhibitors of (1,3)-β-D-glucan synthase, an essential enzyme in fungal cell wall synthesis and integrity (11, 12). Caspofungin is the most extensively used echinocandin, especially in the treatment of invasive candidiasis (13, 14). Recently, more attention has been drawn to the immunopharmacological properties of antifungals, for example, echinocandins, whose mode of action has been shown to be dependent on these properties (15, 16).

The superior antifungal activity of the leucine derivative DL-2-hydroxyisocaproic acid (HICA) against C. albicans biofilms compared with that of caspofungin has been demonstrated (17). The efficacy of HICA against a spectrum of planktonically grown bacteria and fungi has been reported (18, 19). HICA is an α-hydroxy amino acid produced during Lactobacillus fermentation and is also found in human tissues (20, 21). It has been used for muscle recovery by professional athletes and for veterinary purposes, such as in animal feed, thus demonstrating its biocompatibility and safety profile (21, 22). Multiple studies have described the potential anti-inflammatory properties of lactobacilli and their metabolic products (23, 24).

The aim of this study was to determine the potential anti-inflammatory effects of HICA in a murine chamber model of C.
albicans biofilm. To elucidate changes in the local inflammatory response, we used immunohistochemistry to detect the expression of immune proteases and other inflammatory mediators belonging to the destructive oxidative tissue cascade, which is known to play a major role in inflammatory diseases such as periodontitis (3). The core of this cascade is characterized by matrix metalloproteinase (MMP) activation by polymorphonuclear neutrophil (PMN)-secreted myeloperoxidase (MPO). Our hypothesis was that HICA attenuates the anti-inflammatory response by altering the expression of tissue proteases and endogenous proinflammatory mediators.

MATERIALS AND METHODS

Ethics statement. All animals in this study were handled in strict accordance with good animal practice as defined in the United Kingdom Animals (Scientific Procedures) Act. Animal experiments were conducted under the ethically reviewed license authorized by the secretary of state to the University of Manchester, Manchester, United Kingdom (license no. PPL 40/3101).

Murine chamber model. A previously published chamber model was adapted for this study (25). The biofilm chamber was structurally based on a diffusion chamber kit (Millipore, Watford, United Kingdom) comprising a semipermeable Durapore membrane with a pore size of 0.45 μm fixed to a Plexiglas ring. A nonpermeable silicon sheet was fixed to the opposite side to face the semipermeable membrane and to close the chamber, and the chambers were sterilized prior to use. A total of 24 male CD1 mice weighing 21 to 24 g were used, but one mouse was lost due to bleeding in surgery. The dorsal flank of each mouse was shaved, and a 2-cm incision was made. The diffusion chamber was implanted subcutaneously so that the semipermeable membrane faced the dorsal muscles and the nonpermeable silicon sheet faced the skin. The wound was closed with nonabsorbable braided silk sutures (Ethicon, NJ), and meloxicam (3 mg/kg of body weight daily) was administered intraperitoneally for 3 days postsurgery. One week after surgery, while the mice were under isoflurane anesthesia, the chambers were injected percutaneously with 100 μl of C. albicans strain SC5314 inoculum (10^6 CFU/mouse). The inoculum was mixed thoroughly before injection, and the inoculum concentration was checked using dilution plating. The mice were left to recover for 5 days, allowing for robust C. albicans biofilms to be formed inside the chambers. Then, 100 μl of 5% (wt/vol) HICA, 10 mg/liter of caspofungin, or phosphate-buffered saline (PBS) was injected percutaneously into the chambers. The mice were euthanized 12 h posttreatment with an overdose of isoflurane. The chambers were collected and the biofilms detached and weighed. Tissues around the chambers were dissected and fixed and stored in 10% formaldehyde until the analyses.

Study design. A total of 24 mice were used in this study. Diffusion chambers (Millipore, Watford, United Kingdom) with a semipermeable membrane facing the tissues were implanted subcutaneously in the dorsal flank of each mouse, and the animals were allowed to recover for 7 days. The mice were divided into one of two main groups, a biofilm group (n = 15) or a noninfected, nonbiofilm group (n = 8). The chambers in the mice in the biofilm group were infected with C. albicans, and a robust biofilm was established over 5 days. The biofilms were treated for 12 h with HICA (n = 8), and caspofungin (n = 3) or PBS (n = 4) was used as a control treatment. The nonbiofilm chambers were treated similarly with HICA (n = 2), caspofungin (n = 3), or PBS (n = 3). The nonbiofilm HICA group was smaller due to the loss of one mouse in surgery (final n = 23). The mice were euthanized posttreatment, and the chambers and surrounding subcutaneous tissue sections were collected from each mouse. The biofilms were detached from the chambers and weighed. To analyze changes in the cellular and tissue structures and the extent of inflammatory response, tissue sections were stained with hematoxylin and eosin (H&E) and for matrix metalloproteinase-8 (MMP-8) or MMP-9, myeloperoxidase (MPO), neutrophil elastase (NE), tumor necrosis factor alpha (TNF-α), interleukin 1-beta (IL-1β), and developmental endothelial locus 1 (Del-1) using the corresponding antibodies. The stained sections were evaluated by light microscopy, and the staining intensities were semiquantified and graded.

Strain and growth conditions. C. albicans strain SC5314 was used in this study (26). The strain was stored at −80°C, plated twice on Sabouraud dextrose agar (Melford, Suffolk, United Kingdom), and incubated at 37°C for 48 h before use to check for viability and purity. A colony was suspended in PBS and mixed well, and the cells were washed twice before adjusting the inoculum using a hemocytometer to correspond to 10^7 CFU/ml. Viable counts were verified by dilution plating. The viabilities of the biofilms were checked by culture after treatment with PBS, caspofungin, or HICA.

Immunohistochemistry. Immunohistochemical staining was performed as described previously (27). Briefly, tissue sections were embedded in paraffin. These paraffin-embedded specimens were sectioned, deparaffinized, and pretreated with 0.4% pepsin, and endogenous peroxidase activity was blocked with H2O2-methanol. Staining was performed using either polyclonal Vectastain Elite rabbit or goat avidin-biotin enzyme complex (ABC) kits (Vector Laboratories, Burlingame, CA, USA). The sections were blocked with normal goat or rabbit serum in 2% bovine serum albumin and incubated with the polyclonal antibodies rabbit MMP-8 (Santa-Cruz Biotechnology, Santa-Cruz, CA, USA), goat MMP-9 (R&D Systems, Minneapolis, MN, USA), rabbit MPO (Hycult Biotechnology, Uden, Netherlands), rabbit NE (Calbiochem, San Diego, CA, USA), goat IL-1β (R&D Systems), goat TNF-α (R&D Systems), and rabbit Del-1 (Proteintech, Chicago, IL, USA). Control sections were incubated with nonimmune rabbit or goat serum. The inflammatory markers were visualized using a biotinylated anti-rabbit or anti-goat secondary antibody and avidin-biotin enzyme complex. 3-Amino-9-ethyl-carbazole was used as a chromogen and Mayer’s hematoxylin (Histolab Products AB, Frölunda, Sweden) as the counterstain. All sections were also stained with hematoxylin and eosin (H&E) for routine histopathology.

The stained sections were evaluated under an Olympus BX61 light microscope, and representative images were taken using an Olympus DP50 camera and analyzed by AnalySIS v.3.2 software (Soft Imaging System GmbH, Muenster, Germany). The immunoreactivities of the tissue sections surrounding the chamber were semiquantified for each protein antibody and graded based on the staining intensity as no staining (−), mild (+), moderate (++), or strong (+++). The results from the semiquantitative analysis were confirmed blindly by a second evaluator, and a trained pathologist examined the histopathology. The distributions in staining intensity within groups were visualized using GraphPad Prism v.5.0 software (GraphPad Software, Inc., La Jolla, CA, USA).

Statistical analysis. The data were analyzed using GraphPad Prism v.5.0 software (GraphPad Software, Inc.). Univariate analysis of variance (ANOVA) was used for comparisons between biofilm weights. P values of <0.05 were considered significant.

RESULTS

C. albicans biofilms. No significant differences were measured in the biofilm weights after treatment for 12 h with HICA, caspofungin, or PBS (P not significant). The lowest average weight (18.5 ± 7.1 mg) was measured for the biofilms treated with HICA, whereas the highest mean weight (20.8 ± 7.9 mg) was measured for caspofungin-treated biofilms. All the biofilms were viable after treatment with PBS, caspofungin, or HICA.

Histopathology. Upon histopathological examination (H&E staining), typical components of wound healing and various levels of inflammation were seen in all of the tissue samples. Debris and fibrin together with various amounts of polymorphonuclear neutrophils (PMNs) were present in the tissues that had been resting against the semipermeable membrane of the chamber. The underlying granulation tissue presented various degrees of mixed in-
flammatory infiltrate. The intensities of the inflammatory responses were different within and between the groups. The degrees of cellular density and edema also varied. When the biofilm and noninfected, nonbiofilm groups were compared, marked differences were seen. In all of the nonbiofilm sections, the granulation tissue was a thin layer and inflammation was mainly composed of lymphocytes, plasma cells, and monocytes. The densities were altogether moderate. Interestingly, the HICA-treated biofilm group showed an inflammatory response similar to that seen in the nonbiofilm control sections, that is, a predominantly mononuclear cellular infiltrate that was moderate in density. However, a PMN infiltrate in the biofilm group was observed superficially compared to observations in sections in the nonbiofilm group.

Sections from the two biofilm groups treated with either caspofungin or PBS showed thicker bands of granulation tissue with dense inflammatory cell infiltrates, composed mostly of macrophages and PMNs. In addition, inflammatory foci in muscle and adipose layers and abscess formations that varied in size were frequently observed in the biofilm group, particularly in the controls treated with caspofungin or PBS.

**Semiquantitative immunohistochemical analysis.** Staining for MMP-8, MMP-9, MPO, NE, IL-1β, and TNF-α was predominantly localized in the inflammatory cells in all groups. In the biofilm group, the staining for MPO, MMP-8, and MMP-9 was less intense after HICA treatment than after caspofungin or PBS treatment (Fig. 1 and 2A and B). The most distinct differences between the treatment groups were observed in the staining intensities of MPO and MMP-9. However, no marked differences were seen in MPO, MMP-8, or MMP-9 staining intensities between the treated and untreated noninfected, nonbiofilm controls (Fig. 1 and 2A and B). In general, staining for MPO, MMP-8, and MMP-9 was stronger in the biofilm group than in the nonbiofilm group. The staining of NE was stronger in the biofilm group than in the nonbiofilm group, although less intense than that for MPO (Fig. 1). However, in contrast to MPO, no marked differences could be seen between the treatments for NE. The expression of IL-1β was also stronger in the biofilm group, with minimal differences between treatments (Fig. 1). In contrast, minimal TNF-α staining was seen in sections from all treatments and groups (Fig. 1).

In the nonbiofilm group, Del-1 was strongly expressed by endothelial cells in sections from all treatment groups (Fig. 1 and Fig. 2C). The staining was clearly less intense in the untreated and caspofungin biofilm group sections. However, in sections from the HICA-treated group, moderate to strong staining was seen in the endothelial cells adjacent to the chambers.

**DISCUSSION**

This is the first study to address the impact of HICA on the inflammatory response to infection in vivo. Less inflammation was observed in tissues surrounding the biofilm-infected diffusion chamber after treatment with HICA than after caspofungin or PBS treatment. Histopathology showed a predominantly mononuclear cell profile and a less prominent and less dense PMN infiltrate. A decrease in MPO expression was observed after HICA treatment. This correlated with the decreased expression of MMP-9 in tissue sections and indicates a reduced oxidative inflammatory burden as a result of the MPO and MMP-9 cascade. Significant differences in the expression of MMP-8 and NE between the HICA and control groups were not seen.

High expression levels of MMP-8, MMP-9, MPO, and NE have been detected in chronic inflammatory diseases and linked to the loss of soft and hard tissues (3, 28). However, numerous studies have described the anti-inflammatory effect of MMP-8 and have
shown its role in wound healing (27, 29, 30). NE, secreted by PMNs, plays an important role in wound healing, but prolonged secretion and excessive levels can impair the healing process, as observed in chronic wounds (31). This underlines the importance of homeostasis in the expression of immune mediators.

Tissue sections from the caspofungin and PBS biofilm groups showed characteristics of chronic inflammation, since abscess formation and inflammation in deeper tissue layers were frequently observed. This correlated with the staining pattern representing the expression (Fig. 1). In vivo studies have shown that caspofungin exerts its immunomodulatory effects through the morphological changes in the fungal cell wall structure as a result of increasing β-glucan exposure, which leads to an increased inflammatory response (32, 33).

In humans, HICA is a by-product of ketoisocaproic acid (KICA) in the leucine pathway (34). Multiple studies have investigated the immunomodulatory role of leucine, and anticatabolic and anti-inflammatory activities have been observed (35, 36). A study using a combination of herbs and leucine for the treatment of articular diseases showed an induction of IL-1β and strong downregulation of MMP-9 (37), similar to the effects seen in our study. To further support our hypothesis, multiple studies have shown the potential anti-inflammatory effect of *Lactobacillus* metabolites (23, 24). This is relevant because the antimicrobial activity of HICA was discovered in a mixture of fermentation products from *Lactobacillus plantarum* (38, 39).

Interestingly, endothelial cell-secreted protein Del-1 showed stronger expression in the HICA-treated biofilm group than in those treated with either caspofungin or PBS. The staining profile was similar to that of sections from nonbiofilm controls (Fig. 1 and 2C). Del-1 has been linked to inflammatory diseases such as periodontitis and Sjögren syndrome (40, 41). In addition to its role as an inhibitory agent against intercellular adhesion molecule 1 (ICAM-1)-dependent neutrophil adherence to lymphocyte function-associated antigen 1 (LFA-1)-integrin and extravasation, a recent study described a Del-1 inhibitory action against ICAM-1-dependent chemokine release from neutrophils, thus potentiating its regulatory role and further extending it to inflammatory circuitry (42). Our observations support the results of others and provide evidence of a potential anti-inflammatory shield induced by HICA.

A single dose of HICA or caspofungin induced no major inhibitory activity against *C. albicans* biofilms in a 12-h incubation. This is in line with the results of previous studies where no major antifungal activity against fully mature biofilms was observed in caspofungin lock therapy in vivo when similarly short treatment times were used (43). In our model, biofilms were left to form for 5 days before treatment. The properties and structures of such biofilms have been shown to correlate with mature (24-48 h) *in vitro* biofilm (44). In our *in vitro* study, HICA was highly active against mature biofilms after 24 h of treatment (17). The different inflammatory responses observed after HICA treatment may have been affected by its deteriorating effect on the biofilm ultrastructure and fungal cells.

Ours is one of the few studies presenting the inflammatory response against fully mature *C. albicans* biofilms in vivo. An *in vitro* coculture study with *C. albicans* biofilms and mononuclear cells showed pro- and anti-inflammatory cytokine profiles strikingly different from those of planktonic cells (45). IL-1β was significantly upregulated and, in contrast, TNF-α was significantly downregulated. Multiple cell culture and *in vivo* studies have shown similar downregulation of TNF-α in bacterial biofilm infections (46–48). Our findings are in line with those of previous studies and further support the view that biofilms induce a distinct immune response (Fig. 1). Interestingly, a recent study showed
that neutrophils can modulate the inflammatory response by inhibiting the expression of TNF-α and IL-1β (49).

HICA can increase protein synthesis and improve muscle recovery after immobilization-induced atrophy (50). The induction of protein synthesis was interpreted to occur through the activation of mammalian target of rapamycin (mTOR) signaling. Interestingly, innate inflammatory responses induced by bacteria, fungi, parasites, and viruses have also been shown to be regulated by the mTOR pathway (51, 52). In addition, protection against mucosal damage during C. albicans infection is mediated through mTOR activation (53). These findings provide evidence for the potential action of HICA to exert its anti-inflammatory and protective effects and should be addressed in future studies.

Biofilm infections are challenging to manage, especially in patients with a compromised immune system. In addition to the efficacy of antimicrobial agents against microbial pathogens, attention should be paid at their immunomodulatory activities. Considering its antimicrobial efficacy and anti-inflammatory activities, HICA may provide a huge therapeutic potential in the treatment of chronic biofilm infections and inflammation, such as those seen with chronic wounds.

ACKNOWLEDGMENTS

This work was financially supported by the Biotechnology and Biological Sciences Research Council, the Engineering and Physical Sciences Research Council, EU Framework 7, the Finnish Dental Society Apollonia, the Fondo Nacional de Desarrollo Científico y Tecnológico, Gilead Sciences Research Council, EU Framework 7, the Finnish Dental Society Apollonia, the Helsinki University Central Hospital Re, the Fondo Nacional de Desarrollo Científico y Tecnológico, Gilead Sciences Research Council, the Engineering and Physical Sciences Research Council, the Finnish Dental Society Apollonia, the Helsinki University Central Hospital Re.

REFERENCES

1. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15:167–193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
2. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318–1322. http://dx.doi.org/10.1126/science.284.5418.1318.
3. Hajishengallis G. 2014. Immunomicrobial pathogenesis of periodontitis: biofilms in the manufacture of a medicament for the treatment of inflammation” (39), but has not received any royalties regarding this patent. P.W. is the chief scientific officer, the director, and a share.
4. Trostrup H, Thomsen K, Christoffersen L, Hougen HP, Bjarnsholt T, Jensen PO, Kirkby N, Calum H, Hoiby N, Moser C. 2013. Pseudomonas aeruginosa biofilm aggravates skin inflammatory response in BALB/c mice. Wound Repair Regen. 21:292–299. http://dx.doi.org/10.1111/wrr.12016.
5. Brown GD, Denning DW, Gow NA, Levitt SM, Netea MG, White TC. 2012. Hidden killers: human fungal infections. Sci. Transl. Med. 4:165rv113. http://dx.doi.org/10.1126/scitranslmed.3004404.
6. Anderson GG, O’Toole GA. 2008. Innate and induced resistance mechanisms of bacterial biofilms. Curr. Top. Microbiol. Immunol. 322:85–105. http://dx.doi.org/10.1007/978-3-540-75418-3_5.
7. Ramage G, Robertson SN, Williams C. 2014. Strength in numbers: antifungal strategies against fungal biofilms. Int. J. Antimicrob. Agents. 43:114–120. http://dx.doi.org/10.1016/j.ijantimicag.2013.10.023.
8. Xu H, Sobue T, Thompson A, Xie Z, Poon K, Ricker A, Cervantes J, Diaz PII, Dongari-Bagtzoglou A. 2013. Streptococcal co-infection augments Candida pathogenicity by amplifying the mucosal inflammatory response. Cell Microbiol.
9. Nett JE, Marchillo K, Spiegel CA, Andes DR. 2010. Development and validation of in vitro C. albicans biofilm denture model. Infect. Immun. 78:3650–3659. http://dx.doi.org/10.1128/IAI.00480-10.
10. Johnson CC, Yu A, Lee H, Fidel PL, Jr, Noverr MC. 2012. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect. Immun. 80: 1736–1743. http://dx.doi.org/10.1128/IAI.00019-12.
11. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arzani-Aldaghi S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikos G, Richardson MD, Rolides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Microbiol. Infect. 18(Suppl 7):S19–S57. http://dx.doi.org/10.1111/j.1469-0691.2012.
12. Deresinski SC, Stevens DA. 2003. Caspofungin. Clin. Infect. Dis. 36: 1445–1457. http://dx.doi.org/10.1086/375080.
13. Pfaffer M, Boyken I, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Candida species to anidulafungin, caspofungin, and micafungin. J. Clin. Microbiol. 49:624–629. http://dx.doi.org/10.1128/JCM.02120-10.
14. Pfaffer MA, Boyken I, Hollis RJJ, Messer SA, Tendolkar S, Diekema DJ. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760–763. http://dx.doi.org/10.1128/JCM.44.3.760-763.2006.
15. Ben-Ami R, Lewis RE, Kontoyiannis DP. 2008. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin. Infect. Dis. 47:226–235. http://dx.doi.org/10.1086/589290.
16. Lewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. 2014. Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrob. Agents Chemother. 58:1738–1743. http://dx.doi.org/10.1128/AAC.02408-13.
17. Nieminen MT, Novak-Frazer L, Rautemaa V, Rajendran R, Sorsa T, Ramage G, Bowyer P, Rautemaa R. 2014. A novel antifungal is active against Candida albicans biofilms and inhibits mutagenic acetaldehyde production in vitro. PLoS One 9:e97864. http://dx.doi.org/10.1128/IAI.00480-10.
18. Sakko M, Moore C, Novak-Frazer L, Rautemaa V, Sorsa T, Hietala P, Jarvinen A, Bowyer P, Tjaderhane L, Rautemaa R. 2014. 2-Hydroxyisocaproic acid (HICA): a new potential antifungal activity of cell wall-active antifungals. Antimicrob. Agents Chemother.
19. Sakko M, Tjaderhane L, Sorsa T, Hietala P, Jarvinen A, Bowyer P, Rautemaa R. 2012. 2-Hydroxyisocaproic acid (HICA): a new potential topical antibacterial agent. Int. J. Antimicrob. Agents. 39:539–540. http://dx.doi.org/10.1111/j.1469-0349.2012.02206.
20. Guo J, Brosnan B, Furey A, Arendt E, Murphy P, Coffey A. 2012. Antifungal activity of Lactobacillus against Microsporum canis, Microsporum gypseum and Epidermophyton floccosum. Bioeng. Bugs 3:104–113. http://dx.doi.org/10.4161/bbug.19624.
21. Mero AA, Ojala T, Hulmi JJ, Puurtinen R, Karila TA, Seppala T. 2010. Effects of alpha-hydroxy-isocaproic acid on body composition, DOMS and performance in athletes. J. Int. Soc. Sports Nutr. 7:1. http://dx.doi.org/10.1186/1550-2783-7-1.
22. Böckel KP, Baker DH. 1982. Comparative utilization of the alpha-keto and α- and l-alpha-hydroxy analogs of leucine, isoleucine and valine by chicks and rats. J. Nutr. 112:1929–1939.
23. Jones SE, Versalovic J. 2009. Probiotic Lactobacillus reuteri biofilms produce antibiotic and anti-inflammatory factors. BMC Microbiol. 9:35. http://dx.doi.org/10.1186/1471-2180-9-35.
24. Ramos AN, Gobatto N, Rachid M, Gonzalez L, Yantorno O, Valdez JC. 2013. Effect of Lactobacillus plantarum and Pseudomonas aeruginosa culture supernatants on polymorphonuclear damage and inflammatory response. Int. Immunopharmacol. 18:247–251. http://dx.doi.org/10.1016/j.imppharm.2009.11.007.
25. Rajendran R, Mowat E, McCulloch E, Lappin DF, Jones B, Lang S, Majithiya JB, Warn P, Williams C, Ramage G. 2011. Azole resistance of Aspergillus fumigatus biofilms is partly associated with efflux pump activ-
Anti-Inflammatory Effect of HICA In Vivo

Hietala P, Westermark HW, Jaarma M, Sorsa T, Vaara M. 2014. Protection against epithelial damage during Candida albicans infection is mediated by PI3K/Akt and mammalian target of rapamycin signaling. J. Infect. Dis. 210:1093–1102. https://dx.doi.org/10.1093/infdis/jit824